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The neurotoxm I-methyl-4-phenyl-1,2,3,6-tetrahydropyrldlne (MPTP) was oxldlzed to dlhydropyrldme 
MPDP+ and pyrldme MPP+ by preparations of monoamme oxldase B (MAO B), mcludmg pure human 
hver MAO B monoclonal antlbody complex Km+vp values for MPTP and benzylamme, a preferred MAO 
B substrate, were 316 and 64,uM, respectively 4-Phenyl-1,2,3,6_tetrahydropyrldlne (PTP), the nor derlvatlve 
of MPTP, was also a substrate (KmTapp= 221 PM) MPDP+, MPTP, and MPP+, but not PTP, were found 
to be irreversible mhlbltors of MAO B Our studies support the hypothesis that MPTP IS oxldtzed m prtmate 
bram by MAO B to MPDP+, which IS then converted to MPP+, a maJor metabohte found m the substantla 
mgra 
MPTP MPDP+ MPP+ Monoamine oxldase Substantza mgra Dopamme rnhlbrtron 
1. INTRODUCTION vent the dopamme-depleting effect of the drug. 
Several studies suggest that 1-methyl-Cphenyl- 
1,2,3,6_tetrahydropyridme (MPTP) must be 
metabohzed to produce Parkmson-hke symptoms 
[l-4]. Monoamme oxidase (MAO, EC 1.4.3.4), 
the major intracellular enzyme which degrades bio- 
genie ammes m mammals [5], is thought to play an 
important role in this process. Chiba et al. [l] 
found that m rat brain mitochondrial fracttons, 
MPTP can be converted by MAO B, one of the 
two forms of this enzyme, to its correspondmg 
pyridmmm derivattve, MPP+, a maJor metabohte 
in primates [6-71. Furthermore, Langston et al. [2] 
have shown that pretreatment of primates with the 
MAO B mhtbnor, deprenyl, prevents the develop- 
ment of MPTP-mduced parkinsonism, while 
studies by Heikktla et al. [3] demonstrate in mice 
that clorgyhne, an MAO A inhibitor, does not pre- 
Our studies [8] show that MPTP is metabolized 
to MPP+ by MAO B via the drhydropyridine 
MPDP+. Simultaneously, Salach et al 191 
demonstrated that homogeneous preparations of 
bovine liver MAO B and human placental MAO A 
oxrdize MPTP with K,,, values similar to those of 
benzylamme. Both forms of the enzyme were rr- 
reversrbly inactivated when incubated with high 
concentrations (l-5 mM) of MPTP. Collectively, 
these data led us to examine the kinetic properties 
of human MAO B with MPTP as substrate, smce 
highly purified preparations of human or other 
primate MAO B had not previously been studied. 
2. MATERIALS AND METHODS 
+ TO whom correspondence should be addressed 
+ Visiting Scientist from A Mrckiewicz Umversity, Poz- 
nan, Poland 
One source of enzyme used in these studies was 
pure, catalytically active MAO B : monoclonal an- 
tibody complex (MAO B : MAO B-lC2) prepared 
from human autopsy liver as described by Pate1 et 
al. [lo], using a well characterized monoclonal an- 
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tibody [MAO B-1C2) which recognizes human 
MAO B but not MAO A [ll,l2]. MAO B:MAO 
B-1C2 was studied because MAO B has not yet 
been separated from MAO B-lC2 in catalytically 
active form, nor have preparations of pure human 
MAO B with hrgh catalytic activity been obtained 
by other methods. Liver was the most appropriate 
source of human MAO B because autopsy brain is 
difficult to obtain. The substrate preferences and 
molecular activities of human MAO B in hver and 
brain appear to be essentrally identical [ 131. Crude 
extracts of human hver mitochondria and partially 
purified bovine liver MAO B were prepared and 
studied as descrrbed in [8,9]. 
MPTP and 4-phenyl-1,2,3,6_tetrahydropyridine 
(PTP) were purchased from Aldrich. MPDP+ and 
MPPt were prepared and chara~erlzed as m [S] 
(see fig. 1 for structures). These compounds exhibit 
different UV spectra, and the oxidation of MPTP 
181 and PTP (unpublished) into then corre- 
sponding dihydropyridmmm derivatives can be 
followed spectrophotometrrcally at 340 nm (EM = 
1 30 x 104) in aqueous solutions. 
gdg-~ 
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F1g.1 Structures of MPTP, MPDP” and MPP+ 
Table 1 
Kmettc parameters of MPTP, PTP and benzylamlne oxtdauon by human and bovine hver MAO 
preparatrons 
Source of enzyme Substrate K m.aPP v max,app 
fuM) (nmol/min per mg) 
Partially purified bovrne liver MAO B MPTP 179 34 6 
benzy~amine 128 76 9 
Human liver mnochondrtal extracts MPTP 152 2 47 
(1 5% Trlton X-100) PTP 282 4 17 
benzylamme 34 11 2 
Pure human hver MAO B * MAO B- 1 C2 MPTP 316 229 
PTP 221 196 
benzylamme 64 880 
Partrally purtfted bovine MAO B was assayed spectrophotometricaliy m trtphcate wrth 9 different 
concentrattons of MPTP (40-650 ,uM, A 340~~) and benzylamme (25-250 pM, AzsD,,,,,) Km,app and 
Vmax,app values were calculated by linear regresston analysts of the data plotted as l/v against l/S 
The correlatton coefftctents of the regresston lines were 0 99 for MPTP and 0 98 for benzylamme 
and the values of the trrphcate pomts were + 8% SD Protein concentrations used for the enzyme 
activny measurements were 11 pg protem per sample for both substrates Human hver 
mttochondrrai extracts were assayed m trtphcate for actrvrty at 9 concentratrons of MPTP 
(20-200 FM), PTP (20-480 PM) and benzylamme (20-480 PM) Values for IY,,,+~~ and Vmax,ar,pp 
were calculated as stated above with correiatton coefftctents of 0 99, 0.97, 0.98, respecttvely. The 
means for the triphcates were 4 Solo SD for benzylamme and MPTP and rt 10% SD for PTP. 
Protem Concentrations used for these measurements were 242 pg for MPTP and PTP and 48 fig for 
benzytamme per sample analyzed Pure human hver MAO B MAO B-ICI? was assayed at 9 
concentrattons tn triphcate of MPTP (40-400/1M), PTP (40-4OOpM) and benzylamme 
(10-160 pM). iG,,app and V,,,ax,app values were obtained as described above, correlatron coefftctents 
were 0 98,O 98,0 99, respectrvely. The means of the trrphcates were + 5% SD for MPTP and PTP 
and k 8% SD for benzylamme MAO B protem concentratrons were 6.7 gg per sample for MPTP 
and PTP and 0 67 pg per sample for benzylamme 
22s 
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3. RESULTS 
Table 1 shows the kinetic properties for the ox- 
idation of MPTP and PTP to their correspondmg 
drhydropyridimum analogs by pure human liver 
MAO B : MAO B-lC2 and detergent extracts of 
human liver mitochondrra. Km,app values for 
MPTP were similar, although not identical, m 
these 2 preparations. Km,app values for ben- 
zylamme, however, were approx 5-fold lower than 
for MPTP A comparison of MPTP and ben- 
zylamme oxidation by partially purified bovme 
MAO B (about 80% pure as Judged by examma- 
tion on SDS gels), which was prepared accordmg 
to Salach [ 141, gave similar K,,,,app values (179 and 
129 PM, respectively). In all MAO B preparations 
studied, however, benzylamine was oxidized at a 
2-4-fold faster rate than MPTP. 
MAO B catalytrc activity declined progressively 
when MPTP was used as substrate, suggesting that 
the enzyme was being inactivated. Therefore, the 
effects of MPTP, MPDP+, MPP+ and PTP on 
benzylamme oxidation of MAO B:MAO B-lC2 
were assessed as a function of time. Fig.2 shows 
that after a short initial lag, enzyme inactivation by 
MPTP followed first-order kinetics. MPDP+ and 
MPP+ also inactivated the enzyme complex, but 
PTP (1 mM) had no effect. The pseudo first-order 
rate constants for the inactivation of 
MAO B:MAO B-lC2 were 3.92 x lo-’ mu-’ for 
MPTP (1 mM), 3.48 x lo-’ mu-’ for MPDP+ 
(0.2 mM), and 1.77 x 10e2 mu-’ for MPP+ 
(10 mM) Attempts to recover actrvrty by over- 
night dialysis against buffer were unsuccessful. 
Furthermore, incubation of [3H]MPTP with 
MAO B : MAO B-lC2 resulted m the mcorpora- 
tion of tritium into protein, which could not be 
removed by extensive washing with buffer. 
These results support the concept that MPTP 
can be oxidized by human MAO B to MPDP+, an 
intermediate in the formation of the metabolite 
MPP+. Using crude preparations of MAO B, we 
have shown that MPTP is oxidized to MPDP+ at 
a 5-fold faster rate than MPDP+ 1s converted to 
MPP+ [8]. However, since MPDP+ chemically 
undergoes rapid disproporttonatron at the pH of 
the mcubatron mixture [ 15,161 and has spectral 
properties in water (max 343 nm) which are 
similar to those of MPP+ (max. 293 nm), it is 
presently not possible to determine whether the 
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Fig 2. Irreversible mactlvatton of pure human hver 
MAO B.MAO B-lC2 by MPTP (1 mM, panel A), 
MPDP+ (0 2 mM, panel B), and MPP+ (10 mM, panel 
C) MAO B.MAO B-lC2 (62pg protein) was 
suspended m 50 mM KHzPO~/K~HPO~ buffer, pH 7.4, 
and incubated at 30°C with 1 mM MPTP, 0.2 mM 
MPDP+, and 10 mM MPP+, respectively At the times 
mdtcated, trtphcate lop1 ahquots were removed, added 
to the assay cuvettes, and diluted to 1 0 ml wtth the 
assay solutron, whtch contamed 3 mM benzylamme m 
50 mM potassmm phosphate buffer, pH 7 4 Imttal 
rates were determined from 0 to 2 mm by measurmg the 
increase m absorption at 250 nm using a Beckman 
DU-7U spectrophotometer Panel D shows linear 
regression analyses of the data; the correlatton 
coefftcients m all cases were >0 99 (0) Control or 
1 mM PTP (panel A), (A) 1 mM MPTP, (A) 0 2 mM 
MPDP+; (0) 10 mM MPP+ The calculated rate 
constants k (mu-‘) were 3 92 x lo-’ for 1 mM MPTP, 
3 48 x lo-* for 0.2 mM MPDP+ and 1 77 x IO-* for 
10 mM MPP+ Overmght dtalysts vs phosphate buffer 
after lOO-fold ddutton drd not affect the acttvtty 
measurements 
formation of MPP+ from MPDP+ is the result of 
this chemical transformatron or addrtronal en- 
zymatic oxidation. 
MPTP and its oxidation products were found to 
inhibit MAO B irreversibly with potencres ranked 
as follows: MPDP+ > MPTP > MPP+. In con- 
trast, PTP did not inactivate MAO B. The N- 
methyl substrtuent is clearly Important for nrever- 
sable enzyme mhibition. 
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4. DISCUSSION 
The relevance of MAO inactivation to the 
neurotoxrc effects of MPTP in vivo IS unclear. Pa- 
tients treated for endogenous depression with ir- 
reversible inhibitors of MAO A and B (e.g., 
tranylcypromme) do not develop parkinsonian 
symptoms [ 171. Furthermore, if irreversible inhrbi- 
tion of MAO B were the crucial event for 
neurotoxicity, many MAO B-containing neurons 
would presumably undergo similar damage. In 
fact, however, we have shown that MAO B 1s not 
found m the highly sensitive cells of the substantra 
nigra. Our localization studies of MAO A and 
MAO B m Macaca cynomolgus monkey brain, 
performed with MAO type-specific monoclonal 
antibodies, revealed that MAO B is localized large- 
ly in serotonergic neurons and not dopammergic 
neurons, while MAO A is localized in 
catecholammergic regions, including the substan- 
tia nigra [18]. 
Given these patterns of drstrrbutron, we 
hypothesize that MAO B catalyzes the oxidation 
of MPTP to MPDP+ and MPP+ in serotonergrc 
neurons which impinge either on dopammergic 
cells in the substantra nigra or their terminals m the 
striatum, or m MAO B-containing, astrocytic ghal 
cells. These metabolites may be transported out of 
these cells and taken up by neurons in the substan- 
tra mgra. After this work was completed, Javitch 
et al. [19] also proposed that MPP+ may be pro- 
duced m astrocytes and transported into neurons 
in the substantra nigra. Previous studies show that 
48-72 h after MPTP administration to monkeys, 
MPP+ accumulates in the substantra nigra, but 
decreases in surrounding regrons of brain [20]. In 
rats, MPP+ 1s transported into neurons through 
the dopamme uptake system in striatal prepara- 
tions [21]. 
The biologrcal target(s) of MPP+ m neurons of 
the substantra mgra 1s unknown, but one possible 
candidate is MAO A. In vrtro preparations of pure 
human placental MAO A converts MPTP to 
MPP+, an irreversible mhrbitor of this enzyme [9]; 
however, MPTP is a reversible competitrve m- 
hibitor of rat brain MAO A [22]. If MPP+ is an ef- 
fective m vrvo mhrbitor of prrmate neuronal 
MAO A, its accumulation in the substantra mgra 
could interfere with the function of this important 
amme-degrading enzyme and thereby contribute to 
specific neurotoxicity. 
Collectively, the results of our studies of human 
MAO B and those of others using MAO B from 
other mammals [l-4,9] support the hypothesis 
that MPTP IS oxidized by MAO B to compounds 
that can cause significant mhibrtron of both 
MAO A and MAO B. These molecular events 
could contribute to specrfic neuronal toxicity in the 
substantia nigra and lead to Parkinson’s disease. 
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